Express News | Hologic Shares Trims Gain, Last up 0.6%; FDA Says Hologic, Inc. Recalls Biozorb Marker Due to Complications With Implanted Devices
Express News | FDA: FDA Identified Hologic's Recall of Biozorb Marker as a Class I Recall
Express News | Hologic Recalls BioZorb Marker Due To Complications With Implanted Devices
Express News | Hologic, Inc. Recalls Biozorb Marker Due To Reported Complications And Adverse Events With Implanted Devices - FDA
Hologic to Webcast Presentations at Upcoming Investor Conferences
MARLBOROUGH, Mass.--(BUSINESS WIRE)--$HOLX #holx--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences: 2024 Leerink Partners Healt
Meditrina Welcomes Senior Vice President of Global Sales to Lead Expansion Efforts and Manage Rapid Growth
Hologic's (NASDAQ:HOLX) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Hologic, Inc.'s (NASDAQ:HOLX) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive
Hologic Is Maintained at Buy by Argus Research
Hologic Is Maintained at Buy by Argus Research
Argus Adjusts Price Target on Hologic to $95 From $89
Hologic (HOLX) has an average rating of outperform and price targets ranging from $70 to $95, according to analysts polled by Capital IQ.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
A Dive Into Hologic (HOLX) International Revenue Trends and Forecasts
Here Is What to Know Beyond Why Hologic, Inc. (HOLX) Is a Trending Stock
Hologic, Inc.'s (NASDAQ:HOLX) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 38.3x Hologic, Inc. (NASDAQ:HOLX) may be sending very bearish signals at the moment, given that almost half of all companies in the United States have P/E
Analysts Have Conflicting Sentiments on These Healthcare Companies: Community Health (CYH) and Hologic (HOLX)
Lumos Diagnostics Concludes Initial Phase of Development Deal With Hologic for Fetal Fibronectin Test; Shares Jump 6%
Lumos Diagnostics (ASX:LDX) concluded the initial stage of its development agreement, aimed at creating a novel fetal fibronectin (fFN) test for women's health company Hologic, according to a Monday f
Hologic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Decoding Hologic Inc (HOLX): A Strategic SWOT Insight
Hologic Is Maintained at Overweight by JP Morgan
Hologic Is Maintained at Overweight by JP Morgan
Earnings Call Summary | Hologic(HOLX.US) Q2 2024 Earnings Conference
The following is a summary of the Hologic, Inc. (HOLX) Q2 2024 Earnings Call Transcript:Financial Performance:Hologic reported Q2 total revenue of $1.02 billion and non-GAAP earnings per share of $1.0
Hologic, Inc. (NASDAQ:HOLX) Q2 2024 Earnings Call Transcript